←
Christopher Sweeney, MBBS1,098 posts
Christopher Sweeney, MBBS avatar✓

Christopher Sweeney, MBBS ✓

@ChrisSweens1

Cancer Researcher & Oncologist Director @SAiGENCI and Prof at Adelaide Uni. Views mine

◷ Joined July 2015▧ 74 Photos and videos
Oncology Tube avatar
⟳ Christopher Sweeney, MBBS retweeted
Oncology Tube@oncologytube·Nov 3

VIDEO: Xtandi instead of an older antiandrogen with RT + 2 yrs ADT in high-risk prostate cancer? ENZARAD (JCO, Oct 24, 2026): 8-yr MFS 74% vs 72%, HR 0.88 🧬⚠️ 👉 oncologytube.com/xtandi-enza… 🔹 Phase 3, open-label, n=802: enzalutamide 24 mo vs older NSAA 6 mo, both with RT + 24 mo ADT; median follow-up 92 mo 🔹 8-yr OS 83% vs 80% (HR 0.87); PSA PFS favored enzalutamide (HR 0.78) 🔹 Exploratory subgroups (hypothesis-generating only): MFS HR 0.47 with planned pelvic nodal RT, 0.43 in cN1 ENZARAD does not support routinely adding enzalutamide in unselected high-risk disease. First presented at ESMO 2025 (LBA86). @OncoAlert @Prof_IanD @ChrisSweens1 @DocJarad @DrLesterColl @Adam_Weiner535 @zklaassen_md @Kenrickng1 @brookmans76 @HimanshuNagarMD @AndreaNecchi @TonyFelefly @DrPaulNguyen @VedangMurthy @piet_ost @DrSrinivas_C @BourlonMaite @Silke_Gillessen @DrSpratticus @PCaParker @PaulSargos @_ShankarSiva @PBlanchardMD @NicholasZaorsky @ChadTangMD @EAntonarakis @DrRanaMcKay @neerajaiims @Prof_Nick_James @WallisCJD @Albert0Briganti @amerseburger @ChapinMD @DrScottTagawa @PBarataMD #ProstateCancer #PCSM #GUOnc #RadOnc #MedOnc #OncologyTube

Post attachment
Adam B. Weiner, MD avatar
⟳ Christopher Sweeney, MBBS retweeted
Adam B. Weiner, MD@Adam_Weiner535·Oct 31

🚨 ENZARAD (ANZUP 1303): 2 years of enzalutamide did not improve metastasis-free survival when added to RT + ADT in high-risk/locally advanced #prostatecancer 🚨 @JCO_ASCO 👥 802 pts, high-risk localized or locally advanced PCa (incl cN1) 📊 Open-label phase 3 RCT, definitive prostate RT + 24 mo ADT 💊 Enzalutamide 160mg daily x24 mo vs older NSAA x6 mo ⏱️ Median f/u 92 mo ✅ 8-yr MFS on conventional imaging 74% vs 72%, HR 0.88 (0.67-1.15), P=0.34, not significant ✅ No OS benefit ✅ Prespecified subgroup w/ planned pelvic nodal RT (n=324): HR 0.47 (0.29-0.76), Padj=0.004 ⚠️ Subgroup signal is hypothesis-generating; grade 3-5 AEs 46% in both arms 🎯 Enzalutamide on top of RT + 2 yr ADT did not improve outcomes overall, potential signal with pelvic nodal RT subgroup 🔗 doi.org/10.1200/JCO-26-01794 @urotoday @UrologyTimes @PCF_Science @SbrtSean @ChrisSweens1 @Prof_IanD @UroOnc @SUO_YUO

Post attachmentPost attachmentPost attachmentPost attachment
Andrea Necchi, MD, FASCO avatar
⟳ Christopher Sweeney, MBBS retweeted
Andrea Necchi, MD, FASCO@AndreaNecchi·Oct 30

This is an important release in @JCO_ASCO in conjunction with #ESMO26 #DASL HiCaP trial. Identifying pts who benefit the most from intensified treatment is a work in progress. @ASCO @myESMO @ChrisSweens1 #ENZARAD @Prof_IanD et al. @OncoAlert ENZARAD (ANZUP 1303): Phase 3 Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate Cancer | Journal of Clinical Oncology ascopubs.org/doi/pdf/10.1200…

Post attachment
Sabine D. Brookman-May avatar
⟳ Christopher Sweeney, MBBS retweeted
Sabine D. Brookman-May@brookmans76·Oct 25

Positive DASL-HiCaP results presented at #ESMO26 @niazi_Dr7 👍Adding #darolutamide to ADT + RT in very-high-risk #ProstateCancer improved ✅4-year MFS (95% vs 88%; HR 0.42), ✅delayed CRPC (HR 0.22) ✅increased time to subsequent hormonal therapy (HR 0.36) All clinically meaningful benefits, while OS remains immature. #ProstateCancer #Radiationtherapy #UrologicOncology @oncodaily @OncoDailyGU @urotoday @ChrisSweens1

Post attachmentPost attachmentPost attachmentPost attachment
Sean McBride avatar
⟳ Christopher Sweeney, MBBS retweeted
Sean McBride@seanmmcbride·Oct 24

1/n Major congrats to our DASL team, especially to @ChrisSweens1 and @niazi_Dr7, and a big thanks to the patients. Working with @ANZUPtrials and @ThePCCTC on DASL as US lead has been a career highlight. I'd contend this establishes a new standard of care in DASL very-high risk PCa. The conventional-image defined MFS benefit with the addition of Darolutamide to RT+ADT was extraordinarily robust; the DSMC recommended reporting out at IA. #ESMO26, #radonc, #medtwitter. @MSKCancerCenter @MSK_RadOnc. #pcsm Brief 🧵

Post attachmentPost attachmentPost attachmentPost attachment
Tom Powles avatar
⟳ Christopher Sweeney, MBBS retweeted
Tom Powles@tompowles1·Oct 24

Darolutamide with ADT and locoregional radiation therapy (RT) in high-risk prostate cancer (DASL) showed Darolutamide reduced the risk of relapse and time to CRPC. Tolerably was good. It’s imporant to identity which patients benefit, as mortality is low, and whether latest staging with PSMA-PET changes things #ESMO26 @Silke_Gillessen @ChrisSweens1

Post attachmentPost attachmentPost attachmentPost attachment
Tom Powles avatar
⟳ Christopher Sweeney, MBBS retweeted
Tom Powles@tompowles1·Oct 24

Rather a brilliant discussion at the presidential #ESMO26 for the DASL very high risk prostate cancer trial The future is patient selection. The clearest indication is in pateints with N1 disease supported by results from thr other trials @OncoAlert @ChrisSweens1 @Uromigos

Post attachment
OncoAlert avatar
⟳ Christopher Sweeney, MBBS retweeted
OncoAlert@OncoAlert·Sep 29

Dear GU Colleagues at #ASTRO26 ! Join us at the first LPCCC – Localised Prostate Cancer Consensus Conference, where challenging and unresolved questions in Prostate Cancerwill be discussed, debated and brought into focus. #LPCCC27 JUST NOW CALL FOR ABSTRACTS ARE OPEN apccc.org/call-for-abstracts… 🔬 We invite our colleagues in #ProstateCancer to submit their abstracts and contribute to shaping the discussion around the diagnosis and clinical management of men with localised prostate cancer. LPCCC is a genuine evolution of the APCCC family, extending the consensus-conference concept to localised disease, with a particular focus on areas where evidence, guidelines and clinical practice leave important questions unanswered. 📅 LPCCC 2027: 29 April – 1 May 2027 Two days of high-level presentations, discussion and debate will bring together the available literature, evidence and expert consensus to address the questions that matter most in everyday clinical practice. @APCCC_Lugano, @BertrandTOMBAL, @ChrisSweens1, @jmmrad, @drjefstathiou, @CaPsurvivorship, @LoebStacy, @charlesryanmd, @AarmstrongDuke, @Ecastromarcos, @LVM_Walz, @piet_ost, @Nicola_Fossati, @AnthonyMJoshua, @Prof_Nick_James, @VedangMurthy, @AttardLab, @Silke_Gillessen, @AOmlin, @ProfKHerrmann Pinging @AmandaNizamMD, @scocmem, @nataliagandur, @gu_onc, @tompowles1, @brian_rini, @declangmurphy, @cdanicas, @neerajaiims

0:40
Erik J. avatar
⟳ Christopher Sweeney, MBBS retweeted
Erik J.@PrblmXpert·Sep 23

Genomic classifiers are shifting mHSPC treatment decisions from one-size-fits-all to evidence-based selection. I find the ENZAMET analysis a strong example of how validated assays can inform which patients truly benefit from docetaxel.

OncoAlert avatar
⟳ Christopher Sweeney, MBBS retweeted
OncoAlert@OncoAlert·Sep 16

Is 85 really “too old” for intensive prostate cancer treatment? That question takes centre stage in our latest LIVE FROM LUGANO discussion from #APCCC26 , where Dr. Chris Sweeney🇦🇺, Dr. Dana Rathkopf 🇺🇸 and Dr. Bertrand Tombal🇧🇪 explore the challenges of treating older patients with advanced #ProstateCancer Rather than relying on chronological age alone, the conversation looks at: 🔹 Biological age and frailty 🔹 Comorbidities and polypharmacy 🔹 Cognitive function and social support 🔹 The role of geriatric assessment, including the G8 score 🔹 Treatment de-escalation and dose modification 🔹 Balancing treatment tolerability with the risk of rapid disease progression One key message emerges: age alone may not tell the full story. For some patients, modifying treatment may allow therapy to remain an option rather than excluding it altogether. 🎥 Watch the latest LIVE FROM LUGANO episode and join the conversation. 💬 How does your team approach treatment intensity in older patients with advanced prostate cancer? 🎓 Series Faculty @APCCC_Lugano @BertrandTOMBAL @ChrisSweens1 @jmmrad @drjefstathiou @CaPsurvivorship @LoebStacy @charlesryanmd @AarmstrongDuke @Ecastromarcos @LVM_Walz @piet_ost @Nicola_Fossati @AnthonyMJoshua @Prof_Nick_James @VedangMurthy @AttardLab @Silke_Gillessen @AOmlin @ProfKHerrmann 📣 Pinging @AmandaNizamMD @scocmem @nataliagandur @gu_onc @tompowles1 @brian_rini @declangmurphy @cdanicas @neerajaiims

4:15